Diffuse Cutaneous Aphthosis After Combined Targeted Cancer Therapies and Responsive to Pentoxifylline

被引：0
|
作者：
Larocca, Cecilia A. [1 ,2 ]
Fay, Christopher J. [1 ,2 ]
Hirner, Jesse P. [3 ]
Meyerhardt, Jeffrey A. [4 ]
Cleary, James M. [4 ]
Dewan, Anna K. [5 ]
LeBoeuf, Nicole R. [1 ,2 ]
机构：
[1] Dana Farber Canc Inst, Ctr Cutaneous Oncol, Dept Dermatol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, 450 Brookline Ave, Boston, MA 02215 USA
[3] Univ Missouri Hlth Care, Dept Dermatol, Columbia, MO USA
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[5] Vanderbilt Univ, Med Ctr, Dept Dermatol, Nashville, TN USA
来源：
JAMA DERMATOLOGY | 2023年 / 159卷 / 10期
关键词：
D O I：
10.1001/jamadermatol.2023.2649
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
This case series describes 3 patients who developed cutaneous aphthosis while taking an epidermal growth factor receptor inhibitor in combination with an MEK inhibitor.
引用
收藏
页码：1136 / 1139
页数：4
相关论文
共 50 条
  • [41] Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer targeted therapies.
    O'Brien, Neil A.
    Huang, Holly K.
    McDermott, Martina S.
    Madrid, Athena
    Luo, Tong
    Ayala, Raul
    Issakhanian, Shawnt
    Gong, Ke Wei
    Lu, Ming
    Zhang, Jun
    Slamon, Dennis J.
    CANCER RESEARCH, 2022, 82 (12)
  • [42] Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review
    Nicolatou-Galitis, Ourania
    Razis, Evangelia
    Galiti, Dimitra
    Galitis, Evangelos
    Labropoulos, Stefanos
    Tsimpidakis, Antonis
    Sgouros, Joseph
    Karampeazis, Athanasios
    Migliorati, Cesar
    ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2015, 120 (06): : 699 - 706
  • [43] Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer
    Goetz, M. P.
    Beeram, M.
    Beck, T.
    Conlin, A. K.
    Dees, E. C.
    Dickler, M. N.
    Helsten, T. L.
    Conkling, P. R.
    Edenfield, W. J.
    Richards, D. A.
    Turner, P. K.
    Cai, N.
    Chan, E. M.
    Pant, S.
    Becerra, C. H.
    Kalinsky, K.
    Puhalla, S. L.
    Rexer, B. N.
    Burris, H. A.
    Tolaney, S. M.
    CANCER RESEARCH, 2016, 76
  • [44] Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies
    O'Brien, Neil A.
    Huang, Holly K. T.
    McDermott, Martina S. J.
    Madrid, Athena M.
    Luo, Tong
    Ayala, Raul
    Issakhanian, Shawnt
    Gong, Ke Wei
    Lu, Ming
    Zhang, Jun
    Slamon, Dennis J.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (05) : 751 - 761
  • [45] Near-infrared/pH dual-responsive nanocomplexes for targeted imaging and chemo/gene/photothermal tri-therapies of non-small cell lung cancer
    Li, Ziying
    Zhu, Lisheng
    Liu, Weiqun
    Zheng, Yilin
    Li, Xudong
    Ye, Jinxiang
    Li, Bifei
    Chen, Haijun
    Gao, Yu
    ACTA BIOMATERIALIA, 2020, 107 : 242 - 259
  • [46] Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature
    Desage, Anne-Laure
    Duruisseaux, Michael
    Lafitte, Claire
    Bayle-Bleuez, Sophie
    Chouaid, Christos
    Fournel, Pierre
    Pierret, Thomas
    CANCER TREATMENT REVIEWS, 2024, 129
  • [47] Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies
    Balkhi, Sahar
    Bilato, Giorgia
    De Lerma Barbaro, Andrea
    Orecchia, Paola
    Poggi, Alessandro
    Mortara, Lorenzo
    VACCINES, 2025, 13 (01)
  • [48] Targeted NIR-responsive theranostic immuno-nanomedicine combined TLR7 agonist with immune checkpoint blockade for effective cancer photothermal immunotherapy
    Yasothamani, Vellingiri
    Vivek, Raju
    JOURNAL OF MATERIALS CHEMISTRY B, 2022, 10 (33) : 6392 - 6403
  • [49] Distinguishing morphologic characteristics of cutaneous immune-related adverse events among patients receiving immune checkpoint inhibitors combined with other anti-cancer therapies
    Asdourian, M. S.
    Jacoby, T. V.
    Shah, N.
    Semenov, Y.
    LeBoeuf, N.
    Reynolds, K.
    Dewan, A. K.
    Chen, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : B13 - B13
  • [50] Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
    Symonds, Lynn
    Linden, Hannah
    Gadi, Vijayakrishna
    Korde, Larissa
    Rodler, Eve
    Gralow, Julie
    Redman, Mary
    Baker, Kelsey
    Wu, Quan
    Jenkins, Isaac
    Kurland, Brenda
    Garrison, Mitchell
    Smith, Julie
    Anderson, Jeanne
    Van Haelst, Carol
    Specht, Jennifer
    CLINICAL BREAST CANCER, 2019, 19 (02) : E283 - E296
12345